HTD 주식 개요 코셉트 테라퓨틱스는 미국에서 중증 내분비, 종양, 대사 및 신경 장애 치료를 위한 약물을 발견하고 개발하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Corcept Therapeutics Incorporated 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Corcept Therapeutics 과거 주가 현재 주가 US$49.18 52주 최고치 US$58.44 52주 최저치 US$19.40 베타 0.52 1개월 변경 -10.68% 3개월 변경 사항 31.22% 1년 변경 사항 66.15% 3년 변화 177.85% 5년 변화 347.09% IPO 이후 변화 391.31%
최근 뉴스 및 업데이트
Corcept Therapeutics Incorporated Announces Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Dec 16
Corcept Therapeutics Incorporated Announces Positive Results in Treatment Phase of CATALYST Trial in Patients with Hypercortisolism (Cushing's Syndrome) and Difficult-To-Control Diabetes Dec 13
Corcept Therapeutics Incorporated Announces Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) Dec 12
Investor sentiment improves as stock rises 33% Nov 07
Third quarter 2024 earnings released: EPS: US$0.46 (vs US$0.31 in 3Q 2023) Nov 01
Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024 Oct 31 더 많은 업데이트 보기
Corcept Therapeutics Incorporated Announces Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Dec 16
Corcept Therapeutics Incorporated Announces Positive Results in Treatment Phase of CATALYST Trial in Patients with Hypercortisolism (Cushing's Syndrome) and Difficult-To-Control Diabetes Dec 13
Corcept Therapeutics Incorporated Announces Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) Dec 12
Investor sentiment improves as stock rises 33% Nov 07
Third quarter 2024 earnings released: EPS: US$0.46 (vs US$0.31 in 3Q 2023) Nov 01
Corcept Therapeutics Incorporated Increases Earnings Guidance for the Year 2024 Oct 31
Corcept Therapeutics Incorporated to Report Q3, 2024 Results on Oct 30, 2024 Oct 24
Investor sentiment improves as stock rises 19% Sep 19
Second quarter 2024 earnings released: EPS: US$0.34 (vs US$0.27 in 2Q 2023) Jul 30
Corcept Therapeutics Incorporated to Report Q2, 2024 Results on Jul 29, 2024 Jul 23
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing’S Syndrome) May 29
Investor sentiment improves as stock rises 17% May 13
First quarter 2024 earnings released: EPS: US$0.27 (vs US$0.15 in 1Q 2023) May 02
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial Apr 30
Corcept Therapeutics Incorporated to Report Q1, 2024 Results on May 01, 2024 Apr 26
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis Apr 15
New minor risk - Shareholder dilution Apr 11
Corcept Therapeutics Incorporated, Annual General Meeting, May 17, 2024 Apr 11
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer Apr 10
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome Apr 02
Full year 2023 earnings released: EPS: US$1.03 (vs US$0.95 in FY 2022) Feb 16
Full year 2023 earnings released: EPS: US$1.03 (vs US$0.95 in FY 2022) Feb 16
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial Feb 16
Corcept Therapeutics Incorporated to Report Q4, 2023 Results on Feb 15, 2024 Feb 09
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology Jan 29 Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024
Investor sentiment deteriorates as stock falls 34% Jan 02
Now 24% undervalued after recent price drop Jan 02
Third quarter 2023 earnings released: EPS: US$0.31 (vs US$0.32 in 3Q 2022) Nov 02
Corcept Therapeutics Incorporated Appoints Monica Tellado as President, Emerging Markets Nov 02
Corcept Therapeutics Incorporated Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis Oct 27
Corcept Therapeutics Incorporated to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
New major risk - Share price stability Oct 05
Investor sentiment deteriorates as stock falls 19% Oct 04
Chief Scientific Officer recently sold €579k worth of stock Aug 16
Investor sentiment improves as stock rises 21% Aug 09
New minor risk - Share price stability Aug 06
Second quarter 2023 earnings released: EPS: US$0.27 (vs US$0.26 in 2Q 2022) Aug 03
Corcept Therapeutics Incorporated to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Corcept Therapeutics Incorporated Publishes Results of Corcept’S Phase 2 Trial of Relacorilant in Women with Platinum-Resistant Ovarian Cancer Jun 28
Chief Business Officer & Secretary recently sold €959k worth of stock May 14
First quarter 2023 earnings released: EPS: US$0.15 (vs US$0.21 in 1Q 2022) May 05
Corcept Therapeutics Incorporated Revises Revenue Guidance for 2023 May 05
Insufficient new directors Apr 01
Full year 2022 earnings released: EPS: US$0.95 (vs US$0.97 in FY 2021) Mar 02
Corcept Therapeutics Incorporated to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation Feb 14
Corcept Therapeutics Provides Miricorilant Clinical Development Update Dec 09
Chief Business Officer & Secretary recently sold €593k worth of stock Nov 23
Investor sentiment deteriorated over the past week Nov 10
Third quarter 2022 earnings released: EPS: US$0.32 (vs US$0.26 in 3Q 2021) Nov 05 Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2022 Nov 04
Corcept Therapeutics Incorporated to Report Q3, 2022 Results on Nov 03, 2022 Oct 29
Corcept Therapeutics Incorporated Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis Oct 12
Chief Business Officer & Secretary recently sold €1.3m worth of stock Sep 10
Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.23 in 2Q 2021) Aug 04
Corcept Therapeutics Incorporated Reiterates Revenue Guidance for the Year 2022 Aug 04
Corcept Therapeutics Incorporated to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
Corcept Therapeutics Incorporated Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer Jun 30
Investor sentiment improved over the past week Jun 29
Corcept Therapeutics Incorporated to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer Jun 07
Chief Business Officer & Secretary recently sold €646k worth of stock May 21
First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.20 in 1Q 2021) May 06
Corcept Therapeutics Incorporated Provides Earnings Guidance for the Full Year of 2022 May 06
Corcept Therapeutics Incorporated, Annual General Meeting, May 31, 2022 Apr 26
Corcept Therapeutics Completes Enrollment in Phase 2 Gratitude Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain Apr 06
Corcept Therapeutics Incorporated Announces Overall Survival Data from its 178-Patient, Randomized, Controlled, Phase 2 Study of Relacorilant Plus Nab-Paclitaxel in Patients with Recurrent, Platinum-Resistant Ovarian Cancer Apr 01
Investor sentiment improved over the past week Feb 22
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 16
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Fiscal 2022 Feb 16
Corcept Therapeutics Incorporated to Report Q4, 2021 Results on Feb 15, 2022 Feb 09
Investor sentiment deteriorated over the past week Dec 09
Investor sentiment improved over the past week Nov 10
Third quarter 2021 earnings released: EPS US$0.26 (vs US$0.19 in 3Q 2020) Nov 05
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer Sep 20
Corcept Therapeutics Incorporated Announces Presentation of Positive Results from Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer at Esmo 2021 Sep 10
Chief Medical Officer Andreas Grauer has left the company Aug 18
Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.25 in 2Q 2020) Jul 31
Corcept Therapeutics Incorporated Announces Preliminary Results from Its Phase 3 Reliant Trial of Relacorilant Combined with Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer Jun 23
Independent Director recently bought €2.7m worth of stock Jun 17
Corcept Therapeutics Incorporated Settles Patent Litigation with Sun Pharmaceutical Industries Limited Jun 16
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.26 in 1Q 2020) May 07 Corcept Therapeutics Incorporated Modifies Its Revenue Guidance for 2021
Corcept Therapeutics Incorporated Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess Mar 16 Corcept Therapeutics Incorporated Appoints Atabak Mokari as Chief Financial Officer
Full year 2020 earnings released: EPS US$0.92 (vs US$0.82 in FY 2019) Feb 25
Revenue misses expectations Feb 25
CFO & Secretary recently sold €2.7m worth of stock Feb 19
Corcept Therapeutics Incorporated to Report Q4, 2020 Results on Feb 08, 2021 Feb 02
New 90-day high: €25.00 Jan 29
New 90-day high: €22.40 Jan 13
New 90-day high: €20.60 Dec 12
Corcept Therapeutics Incorporated Announces Executive Changes Nov 24 주주 수익률 HTD DE Pharmaceuticals DE 마켓 7D -6.9% -2.5% -2.6% 1Y 66.1% -15.6% 6.9%
전체 주주 수익률 보기
수익률 대 산업: HTD 지난 1년 동안 -15.6 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: HTD 지난 1년 동안 6.9 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is HTD's price volatile compared to industry and market? HTD volatility HTD Average Weekly Movement 8.9% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: HTD 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: HTD 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 코셉트 테라퓨틱스는 미국에서 중증 내분비, 종양, 대사 및 신경 질환 치료를 위한 의약품을 발견하고 개발하는 기업입니다. 내인성 쿠싱 증후군, 제2형 당뇨병 또는 포도당 과민증이 있고 수술에 실패했거나 수술 후보가 아닌 성인 환자의 고코르티솔증에 의한 이차성 고혈당증 치료를 위한 약물인 콜림 정제를 제공합니다. 또한 쿠싱증후군 치료제로 임상 3상 중인 릴라코릴란트, 부신암 및 코르티솔 과다증 치료제로 임상 1b상, 전립선암 치료제로 임상 2상, 백금 내성 난소 종양 치료제로 임상 3상 중인 나브-파클리탁셀과 릴라코릴란트 병용요법을 개발 중입니다.
자세히 보기 Corcept Therapeutics Incorporated 기본 사항 요약 Corcept Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? HTD 기본 통계 시가총액 €5.16b 수익(TTM ) €134.64m 수익(TTM ) €602.41m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) HTD 손익 계산서(TTM ) 수익 US$628.56m 수익 비용 US$9.80m 총 이익 US$618.75m 기타 비용 US$478.27m 수익 US$140.49m
주당 순이익(EPS) 1.34 총 마진 98.44% 순이익 마진 22.35% 부채/자본 비율 0%
HTD 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/22 23:47 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Corcept Therapeutics Incorporated 23 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Tazeen Ahmad BofA Global Research David Buck B. Riley Securities, Inc. Edward Nash Canaccord Genuity
20 더 많은 분석가 보기 
